Clinical Trials Logo

Evan Syndrome clinical trials

View clinical trials related to Evan Syndrome.

Filter by:
  • None
  • Page 1

NCT ID: NCT06014775 Recruiting - Treatment Clinical Trials

Anti-CD38 Antibody Treating Evans Syndrome

2023-D-ES
Start date: December 2023
Phase: Phase 2
Study type: Interventional

A single-center, open-label, off-label use investigator-initiated clinical study with safety run-in to explore the clinical activity and safety of Anti-CD38 Antibody in adult ES patients who have not responded adequately or relapsed after first-line treatment and at least one second-line therapy including immunosuppressive agents, Anti-CD20 Antibody and/or TPO-RA, or those in whom no other second-line treatment options are suitable.

NCT ID: NCT04993885 Recruiting - Clinical trials for Immune Thrombocytopenia

Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies

Start date: September 1, 2021
Phase: Phase 2
Study type: Interventional

This prospective, open-label, single-center, one-arm clinical trial aims at evaluating the efficacy and safety of avatrombopag in Chinese adult Immune Thrombocytopenia (ITP) patients with autoantibodies fail (due to intolerance or resistance) to eltrombopag or herombopag treatment.

NCT ID: NCT04915482 Recruiting - Clinical trials for Connective Tissue Diseases

TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies

Start date: June 6, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

This prospective, open-label, nonrandomized, multicenter clinical trial aims at comparing the efficacy and safety of combined use of TPO-RAs with low-dose anti-CD20 monoclonal antibody vs. the best available therapy(BAT)in adult immune thrombocytopenia with autoantibodies failed (due to intolerance or resistance) to first-line treatment.

NCT ID: NCT04057703 Completed - Immunotherapy Clinical Trials

Balance Benefit / Risk of Immunomodulatory Treatments at the Child and Adolescent for Autoimmune Cytopenia.

VIGICAIRE
Start date: January 18, 2016
Phase:
Study type: Observational

In France, a national prospective cohort for monitoring children and adolescents with autoimmune cytopenia OBS'CEREVANCE is in place since 2004. It is coordinated in Bordeaux by the Center's team. Reference Rare Diseases CEREVANCE. It has been validated by the French Data Protection Authority in 2009 (information note and written consent). It had mid 2013 more of 900 patients, and the data collected make it possible to study intentionally to treat the therapeutic management of patients with Chronic Immune-Thrombocytopenic Purpura, from Autoimmune Hemolytic Anemia, or from EVANS syndrome. This study evaluates efficacy and tolerance at 6 months of treatment immunomodulators prescribed in France in real conditions of use, in children and adolescents under the age of 18, for a Chronic Immune-Thrombocytopenic Purpura, an Autoimmune Hemolytic Anemia or a simultaneous EVANS syndrome.